番茄社区app

Meeting Coverage >

ECTRIMS

Virtual Care May Help Multiple Sclerosis Patients Even After the Pandemic

Early study paves the way to look at how telehealth may fit into MS care

Novel Anti-CD20 Drug Shows Promise in Relapsing MS

Ublituximab bests teriflunomide in head-to-head phase III trials

Some MS Drugs Linked With Worse COVID-19 Outcomes

Registry data looks at risks of hospitalization, ICU admission, ventilation

COVID-19 Hits Black MS Patients Hard

COViMS registry gives first look at outcomes among North American patients

Masitinib Shows Positive Signs in Progressive MS

Tyrosine kinase inhibitor targets innate immune system

Depression, Suicidal Thoughts Prevalent in MS

Burden equally high in relapsing-remitting and progressive multiple sclerosis

Can Tau Predict Early MS Disability?

Multiple sclerosis patients with higher baseline tau had worse prognosis, longitudinal study shows

Serum NfL Levels May Indicate MS Prodromal Phase

Study shows elevated neurofilament light levels 6 years before MS onset

Ofatumumab Cuts MS Relapse Rates, New Brain Lesions

Anti-CD20 monoclonal antibody poised to take on ocrelizumab

Ponesimod Bests Aubagio in Head-to-Head MS Trial

Investigational drug reduces annual relapse rate, shows effects on fatigue

IL-6 Inhibitor Cuts NMO Relapse Rates

Satralizumab reduces attacks in neuromyelitis optica spectrum disorder

Anti-Inflammatory Drug May Offer Benefit in Progressive MS

Ibudilast seems to diminish brain volume loss

Strike Three for Laquinimod in Relapsing MS

Switching endpoints for third phase III trial didn't help

Getting a Handle on Benign MS

Prevalence varies by definition; agreed that disease progression varies widely

Vaccines Tied to Relapses in Neuromyelitis Optica

Retrospective review finds protective factor in immunotherapy

Revised McDonald Diagnostic Criteria Revealed

Recommends using OCBs, both symptomatic and asymptomatic lesions to diagnose MS

European MS Guidance Taking Shape

ECTRIMS teases the first-ever MS drug guideline

Remyelinating Drug Flops in MS

Large placebo response, 'inverted U-shaped' dose-response in phase II trial

Registry Data: Lemtrada More Effective than Competing MS Tx

Better than fingolimod or interferon; comparable to natalizumab

New Ampyra Trial Bolsters MS Efficacy Claims

Walking ability, as reported by patients, significantly improved

Fluoxetine Flops as Progressive MS Therapy

Trial may have been underpowered to detect a benefit

Rituximab Bests MS Drugs in Swedish Registry

Rituximab offered drug survival advantage over fingolimod, natalizumab

HIV Drug Fails in Small MS Trial

Casts doubt on novel theory of MS etiology

Tysabri vs. Gilenya: Studies Conflict on Which Is Superior

Is natalizumab better than fingolimod? Flip a coin

Lemtrada Efficacy Persists Years after Last Dose

Most patients' responses lasted through 5-year follow-up

Skull Size Tied to Disability Risk in MS

BOSTON -- Multiple sclerosis patients with larger intracranial volumes -- a measure of their lifetime maximal brain size -- scored better on cognition and physical function tests than those with smaller skull sizes.

Multiple Sclerosis Risk Tied to Some OCs

BOSTON -- Women using combined oral contraceptives containing norethindrone or levonorgestrel were substantially more likely to develop multiple sclerosis than those not on "The Pill."

Generic Copaxone for MS Passes Clinical Test

BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug.

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.

Repeat Botox OK for Urinary Incontinence in MS Patients

COPENHAGEN -- Long-term treatment with serial onabotulinum toxin A (Botox) of urinary incontinence among multiple sclerosis (MS) patients appeared to be safe and effective, researchers reported here.